Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B

Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B

Background: Understanding the effect of selumetinib on FASI may help elucidate the biology, proliferative potential, and role in neurocognitive changes for these NF1-associated lesions. Methods: Patients with NF1-associated LGG and FASI treated with selumetinib on PBTC-029B were age-matched to untre...

Full description

Bibliographic Details
Main Authors: Natasha Pillay-Smiley, James Leach, Adam Lane, Trent Hummel, Jason Fangusaro, Peter de Blank
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
NF1
FASI
low grade glioma
MEK inhibitor
selumetinib
Online Access:https://www.mdpi.com/2072-6694/15/7/2109

Internet

https://www.mdpi.com/2072-6694/15/7/2109

Similar Items